- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 19.03. | Orchard follows buyout with FDA approval of rare disease gene therapy | ||
| 19.03. | AstraZeneca buys into radiopharmaceuticals with $2.4B deal for Fusion Pharma | ||
| 19.03. | Engrail's precision psychiatry drugs get more buy in from venture investors | ||
| 18.03. | Bluebird, short on cash, takes on $175M in debt financing | ||
| 18.03. | The digital divide: Balancing automation and human interaction regardless of the patient support program model | ||
| 18.03. | Give HCPs a proactive way to reach your field team: Add inbound | ||
| 15.03. | FDA panel backs broader use of J&J, Bristol Myers cell therapies for myeloma | ||
| 15.03. | Bristol Myers cell therapy wins first-of-its-kind approval | ||
| 15.03. | Madrigal, FDA approval in hand, outlines plan to sell MASH drug | ||
| 14.03. | Madrigal wins FDA approval of first drug for MASH | ||
| 14.03. | BIO changes stance, backs bill to limit China's role in US biotech | ||
| 14.03. | AstraZeneca adds another rare disease drug in $800M buyout of startup Amolyt | ||
| 14.03. | J&J, Novo support Asgard's push to make 'in vivo' cell therapies | ||
| 14.03. | German biotech Tubulis cashes in on ADC 'momentum' with €128M financing | ||
| 13.03. | FDA to focus on 'early deaths' in meeting on broader CAR-T use in myeloma | ||
| 13.03. | Merck reveals plans to develop newer HPV shots | ||
| 13.03. | IFM, an unorthodox biotech startup, scores third buyout with Novartis deal | ||
| 12.03. | Allogene taps Arbor in pursuit of 'off-the-shelf' CAR-T therapies for autoimmune disease | ||
| 12.03. | After surprise trial failure, ALS doctors brace for one less treatment option | ||
| 12.03. | Acadia drug fails schizophrenia trial, setting back company's expansion plans | ||
| 11.03. | Roche, following setbacks, turns to its next Alzheimer's drug | ||
| 11.03. | Boehringer, Sosei Heptares team up in schizophrenia drug deal | ||
| 11.03. | Amylyx CEOs look for a path forward following major setback | ||
| 11.03. | J&J's growing rare disease focus brings a potential multi-use treatment to the table | ||
| 11.03. | Biotech stock fundings headed for best quarter in 3 years, Jefferies says |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
